Rani Therapeutics adds Michelle Gilson to board, names her audit chair

Rani Therapeutics Holdings disclosed in an 8-K that Michelle Gilson was appointed to the Board on August 1, 2026, effective immediately, and will serve until the company's next annual meeting, the seating of a successor, or her earlier death, resignation, or removal.¹ She was also named chair of the Audit Committee.¹

Gilson, age 34, most recently served as Chief Financial Officer of Arcellx, Inc. from May 2022 until the company was acquired by Gilead Sciences, Inc. in April 2026.¹ Before that, she worked as a Senior Biotechnology Equity Research Analyst at Canaccord Genuity Group Inc. from 2018 to 2022, rising to Managing Director.¹ Earlier in her career, she held roles at Jefferies LLC as a Senior Associate (2017-2018), Nomura Group as an Associate (2016-2017), Oppenheimer & Co. as an Associate Director (2015-2016), and Goldman Sachs as an Analyst (2014-2015), covering healthcare and biotechnology companies.¹ She holds a B.S. in Business Administration from the University of Southern California.¹

Under the terms of the appointment, Gilson will be paid as a non-employee director under the terms set out in the company's existing director compensation policy, which was filed as an exhibit to its Form 10-Q on May 15, 2026.¹ The filing states there are no arrangements or understandings between the company and Gilson, no family relationship with other directors or officers, and no material interest requiring disclosure under Regulation S-K Item 404(a).¹

The company will also enter into its standard indemnification agreement with Gilson, covering certain expenses she may incur from claims arising out of her board service.¹